Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EPS (Weighted Average and Diluted) (2019 - 2025)

Historic EPS (Weighted Average and Diluted) for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to $0.0.

  • Akebia Therapeutics' EPS (Weighted Average and Diluted) rose 10196.81% to $0.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.08, marking a year-over-year increase of 6521.74%. This contributed to the annual value of -$0.33 for FY2024, which is 1879.39% down from last year.
  • Latest data reveals that Akebia Therapeutics reported EPS (Weighted Average and Diluted) of $0.0 as of Q3 2025, which was up 10196.81% from $0.0 recorded in Q2 2025.
  • Akebia Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.15 during Q2 2022, with a 5-year trough of -$0.51 in Q2 2021.
  • Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.09 (2024), whereas its average is -$0.15.
  • As far as peak fluctuations go, Akebia Therapeutics' EPS (Weighted Average and Diluted) tumbled by 340058.75% in 2024, and later surged by 13333.33% in 2025.
  • Over the past 5 years, Akebia Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.42 in 2021, then surged by 91.61% to -$0.04 in 2022, then soared by 109.2% to $0.0 in 2023, then plummeted by 3400.59% to -$0.11 in 2024, then soared by 101.82% to $0.0 in 2025.
  • Its EPS (Weighted Average and Diluted) was $0.0 in Q3 2025, compared to $0.0 in Q2 2025 and $0.03 in Q1 2025.